| Sumario: | As illegally made fentanyl and congeners continue to drive overdose deaths in the US, experts have called for stronger and longer‐lasting antagonists. A randomized, 4‐period, 2‐treatment crossover replicate‐design study in healthy moderately‐experienced opioid users (n = 24) evaluated the reversal of opioid‐induced respiratory depression (OIRD) by intramuscular (IM) nalmefene 1.5 mg administered by auto‐injector delivering a formulation developed for faster onset, compared to intranasal (IN) naloxone 4 mg. Fentanyl infusions were administered to induce a 50% reduction in minute ventilation (MV). Reversal of OIRD, pharmacokinetics, and safety were investigated under steady‐state fentanyl agonism. For the primary endpoint, nalmefene demonstrated superiority at 5 min with an MV increase of 4.59 L/min, more than twice the 1.99 L/min increase for naloxone (P <.0001). Nalmefene superiority was also demonstrated at 10, 15, 20, and 30 min, while non‐inferiority was demonstrated at 2.5 and 90 min. The time‐course of mean antagonist concentrations correlated with increases in mean MV, peaking at approximately 5‐10 min following nalmefene compared to 20‐30 min following naloxone. Decreases in transcutaneous CO2 (TCO2) followed a similar time‐course with a slight delay. At each threshold of percent reversal (25%‐100%), nalmefene consistently showed a faster time to onset than naloxone. Both antagonist treatments were tolerated with no serious adverse events. This study shows that nalmefene 1.5 mg IM administered by auto‐injector achieved a faster onset, higher magnitude, and longer duration of reversal of OIRD compared to naloxone 4 mg IN and represents another option for the treatment of opioid overdose.
|
|---|